You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBisoprolol
Accession NumberDB00612  (APRD00257)
TypeSmall Molecule
GroupsApproved
DescriptionBisoprolol is a cardioselective β1-adrenergic blocking agent used for secondary prevention of myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. Bisoprolol is structurally similar to metoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At lower doses (less than 20 mg daily), bisoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with daily doses of 20 mg or greater. Unlike propranolol and pindolol, bisoprolol does not exhibit membrane-stabilizing or sympathomimetic activity. Bisoprolol possesses a single chiral centre and is administered as a racemic mixture. Only l-bisoprolol exhibits significant β-blocking activity.
Structure
Thumb
Synonyms
(+-)-1-((alpha-(2-Isopropoxyethoxy)-P-tolyl)oxy)-3-(isopropylamino)-2-propanol
(RS)-1-(4-(2-isopropoxyethoxymethyl)phenoxy)-3-(isopropylamino)-2-propanol
Bisoprolol
Bisoprololum
External Identifiers
  • CL 297939
  • EMD 33512
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-bisoprololtablet5 mgoralAvanstra Inc2011-08-222014-08-21Canada
Ava-bisoprololtablet10 mgoralAvanstra Inc2011-08-222014-08-21Canada
Bisoprololtablet5 mgoralSanis Health Inc2012-10-01Not applicableCanada
Bisoprololtablet5 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Bisoprololtablet5 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Bisoprololtablet10 mgoralSanis Health Inc2012-10-01Not applicableCanada
Bisoprololtablet10 mgoralSivem Pharmaceuticals Ulc2012-06-12Not applicableCanada
Bisoprololtablet10 mgoralSorres Pharma Inc2009-02-262014-06-20Canada
Dom-bisoprololtablet5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-bisoprololtablet10 mgoralDominion PharmacalNot applicableNot applicableCanada
Monocor -(10mg)tablet10 mgoralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222005-03-10Canada
Monocor -(5mg)tablet5 mgoralBiovail Pharmaceuticals Canada Division Of Biovail Corporation2000-06-222009-07-31Canada
Mylan-bisoprololtablet10 mgoralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Mylan-bisoprololtablet5 mgoralMylan Pharmaceuticals Ulc2012-05-02Not applicableCanada
Nu-bisoprololtablet5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-bisoprololtablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-bisoprololtablet10 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-bisoprololtablet5 mgoralPharmel Inc2008-10-30Not applicableCanada
PMS-bisoprololtablet10 mgoralPharmascience Inc2007-12-18Not applicableCanada
PMS-bisoprololtablet5 mgoralPharmascience Inc2007-12-18Not applicableCanada
Pro-bisoprolol - 10tablet10 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Pro-bisoprolol - 5tablet5 mgoralPro Doc Limitee2008-07-04Not applicableCanada
Sandoz Bisoprololtablet5 mgoralSandoz Canada Incorporated2003-04-24Not applicableCanada
Sandoz Bisoprololtablet10 mgoralSandoz Canada Incorporated2003-04-24Not applicableCanada
Teva-bisoprololtablet5 mgoralTeva Canada Limited2005-10-07Not applicableCanada
Teva-bisoprololtablet10 mgoralTeva Canada Limited2005-10-07Not applicableCanada
Zebetatablet, film coated5 mg/1oralTeva Women's Health, Inc.1992-07-31Not applicableUs
Zebetatablet, film coated10 mg/1oralTeva Women's Health, Inc.1992-07-31Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-bisoprololtablet5 mgoralApotex Inc2004-08-10Not applicableCanada
Apo-bisoprololtablet10 mgoralApotex Inc2004-08-10Not applicableCanada
Bisoprolol Fumaratetablet10 mg/1oralRebel Distributors Corp2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralAurobindo Pharma Limited2006-12-27Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2009-08-07Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralAurobindo Pharma Limited2006-12-27Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc2004-06-01Not applicableUs
Bisoprolol Fumaratetablet, film coated5 mg/1oralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.2012-09-24Not applicableUs
Bisoprolol Fumaratetablet10 mg/1oralUnichem Pharmaceuticals (USA), Inc.2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, coated5 mg/1oralAmerican Health Packaging2011-08-01Not applicableUs
Bisoprolol Fumaratetablet, coated5 mg/1oralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralCitron Pharma LLC2006-12-27Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralRebel Distributors Corp2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2009-07-23Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralCarilion Materials Management2009-09-21Not applicableUs
Bisoprolol Fumaratetablet, coated10 mg/1oralEon Labs, Inc.2000-11-16Not applicableUs
Bisoprolol Fumaratetablet5 mg/1oralbryant ranch prepack2009-09-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CardicorBayer
ConcorMerck
ConcoreMerck
DetensielMerck Santé
EmconcorMerck
EmcorMerck
EuradalLacer
IsotenMeda
MonocorBiovail Pharmaceuticals
SoprolHelsinn
Brand mixtures
NameLabellerIngredients
Bisoprolol Fumarate and HydrochlorothiazideEon Labs, Inc.
ZiacTeva Women's Health, Inc.
Salts
Name/CASStructureProperties
Bisoprolol Fumarate
ThumbNot applicableDBSALT001015
Categories
UNIIY41JS2NL6U
CAS number66722-44-9
WeightAverage: 325.443
Monoisotopic: 325.225308485
Chemical FormulaC18H31NO4
InChI KeyInChIKey=VHYCDWMUTMEGQY-UHFFFAOYSA-N
InChI
InChI=1S/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3
IUPAC Name
1-[(propan-2-yl)amino]-3-(4-{[2-(propan-2-yloxy)ethoxy]methyl}phenoxy)propan-2-ol
SMILES
CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzylethers
Direct ParentBenzylethers
Alternative Parents
Substituents
  • Benzylether
  • Phenol ether
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor management of heart failure, angina pectoris, and mild to moderate hypertension and for secondary prevention of myocardial infarction (MI).
PharmacodynamicsBisoprolol is a competitive, cardioselective β1-adrenergic antagonist. Activation of β1-receptors (located mainly in the heart) by epinephrine increases heart rate and the blood pressure causing the heart to consume more oxygen. β1-adrenergic blocking agents such as bisopolol lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. They are routinely prescribed in patients with ischemic heart disease. In addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys causes constriction of blood vessels. Bisoprolol is lipophilic and exhibits no intrinsic sympathomimetic activity (ISA) or membrane-stabilizing activity.
Mechanism of actionBisoprolol selectively blocks catecholamine stimulation of β1-adrenergic receptors in the heart and vascular smooth muscle. This results in a reduction of heart rate, cardiac output, systolic and diastolic blood pressure, and possibly reflex orthostatic hypotension. At higher doses (e.g. 20 mg and greater) bisoprolol may competitively block β2-adrenergic receptors in bronchial and vascular smooth muscle causing bronchospasm and vasodilation.
Related Articles
AbsorptionWell absorbed. Bioavailability > 80%. Absorption is not affected by food. Peak plasma concentrations occur within 2-4 hours.
Volume of distributionNot Available
Protein bindingBinding to serum proteins is approximately 30%
Metabolism

Approximately 50% of the dose is metabolized primarily metabolized by CYP3A4 to inactive metabolites. In vitro studies have shown that bisoprolol is also metabolized by CYP2D6 though this does not appear to be clinically significant. Approximately half the administered dose is excreted in unchanged in urine.

Route of eliminationEliminated equally by renal and non-renal pathways. Approximately 50% of the total orally administered dose is excreted unchanged in urine with the remainder appearing as inactive metabolites. Less than 2% of the dose is excreted in the feces.
Half life9-12 hours; prolonged in the elderly and those with decreased renal function
ClearanceNot Available
ToxicityOral, mouse: LD50 = 100 mg/kg; Skin, rabbit: LD50 = 200 mg/kg; Skin, rat: LD50 = 500 mg/kg. Symptoms of overdose include congestive heart failure (marked by sudden weight gain, swelling of the legs, feet, and ankles, fatigue, and shortness of breath), difficult or labored breathing, low blood pressure, low blood sugar, and slow heartbeat.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Bisoprolol Action PathwayDrug actionSMP00300
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9445
Blood Brain Barrier-0.9077
Caco-2 permeable+0.6149
P-glycoprotein substrateSubstrate0.7785
P-glycoprotein inhibitor INon-inhibitor0.807
P-glycoprotein inhibitor IINon-inhibitor0.7821
Renal organic cation transporterNon-inhibitor0.8568
CYP450 2C9 substrateNon-substrate0.8134
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.6113
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9485
CYP450 3A4 inhibitorNon-inhibitor0.8373
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9766
Ames testNon AMES toxic0.9064
CarcinogenicityNon-carcinogens0.9267
BiodegradationNot ready biodegradable0.8962
Rat acute toxicity2.0089 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7877
hERG inhibition (predictor II)Non-inhibitor0.6611
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Aurobindo pharma ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Unichem pharmaceuticals (usa) inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral5 mg/1
Tablet, coatedoral10 mg/1
Tablet, coatedoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral
Tablet, coatedoral
Tablet, film coatedoral
Tabletoral10 mg
Tabletoral5 mg
Prices
Unit descriptionCostUnit
Condylox 0.5% Gel 3.5 gm Tube304.93USD tube
Condylox 0.5% Solution 3.5ml Bottle143.4USD bottle
Condylox 0.5% gel97.73USD g
Zebeta 10 mg tablet3.6USD tablet
Zebeta 5 mg tablet3.6USD tablet
Bisoprolol fumarate 5 mg tablet1.78USD tablet
Bisoprolol fumarate 10 mg tablet1.24USD tablet
Bisoprolol-Hydrochlorothiazide 10-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 2.5-6.25 mg tablet1.19USD tablet
Bisoprolol-Hydrochlorothiazide 5-6.25 mg tablet1.19USD tablet
Apo-Bisoprolol 10 mg Tablet0.38USD tablet
Novo-Bisoprolol 10 mg Tablet0.38USD tablet
Pms-Bisoprolol 10 mg Tablet0.38USD tablet
Sandoz Bisoprolol 10 mg Tablet0.38USD tablet
Apo-Bisoprolol 5 mg Tablet0.23USD tablet
Novo-Bisoprolol 5 mg Tablet0.23USD tablet
Pms-Bisoprolol 5 mg Tablet0.23USD tablet
Sandoz Bisoprolol 5 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100 °CPhysProp
water solubility2240 mg/LNot Available
logP1.87RECANATINI,M (1992)
Predicted Properties
PropertyValueSource
Water Solubility0.0707 mg/mLALOGPS
logP2.3ALOGPS
logP2.2ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area59.95 Å2ChemAxon
Rotatable Bond Count12ChemAxon
Refractivity92.15 m3·mol-1ChemAxon
Polarizability38.5 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Yoshihiro Iwao, Katsuyuki Ookubo, Katsuhiro Okada, Kunihiro Minami, Shuichiro Yuasa, “Adhesive Pharmaceutical Preparation Containing Bisoprolol.” U.S. Patent US20090169604, issued July 02, 2009.

US20090169604
General ReferencesNot Available
External Links
ATC CodesC07BB07C09BX02C07FB07C07AB57C07AB07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (73.1 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Bisoprolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Bisoprolol.
AbirateroneThe metabolism of Bisoprolol can be decreased when combined with Abiraterone.
AcebutololBisoprolol may increase the hypotensive activities of Acebutolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Bisoprolol.
AcepromazineAcepromazine may increase the hypotensive activities of Bisoprolol.
AcetazolamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetazolamide.
AcetohexamideBisoprolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Acetylcholine.
AcetyldigitoxinBisoprolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Bisoprolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Bisoprolol.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.
AlfuzosinAlfuzosin may increase the hypotensive activities of Bisoprolol.
AlfuzosinBisoprolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Bisoprolol.
AliskirenBisoprolol may increase the hypotensive activities of Aliskiren.
AlprenololBisoprolol may increase the hypotensive activities of Alprenolol.
AmbenoniumAmbenonium may increase the bradycardic activities of Bisoprolol.
AmbrisentanBisoprolol may increase the hypotensive activities of Ambrisentan.
AmifostineBisoprolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Bisoprolol.
AminophyllineBisoprolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Bisoprolol.
AmlodipineAmlodipine may increase the hypotensive activities of Bisoprolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Bisoprolol.
AmodiaquineThe metabolism of Bisoprolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Bisoprolol can be increased when it is combined with Amoxapine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Bisoprolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Apraclonidine.
ApremilastApremilast may decrease the antihypertensive activities of Bisoprolol.
AprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Aprepitant.
ArbutamineBisoprolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Arecoline.
ArformoterolBisoprolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleAripiprazole may increase the hypotensive activities of Bisoprolol.
ArtemetherThe metabolism of Bisoprolol can be decreased when combined with Artemether.
AtazanavirThe metabolism of Bisoprolol can be decreased when combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Bisoprolol.
AtomoxetineThe metabolism of Bisoprolol can be decreased when combined with Atomoxetine.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Bisoprolol.
AzelastineAzelastine may decrease the antihypertensive activities of Bisoprolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Azilsartan medoxomil.
BalsalazideBalsalazide may decrease the antihypertensive activities of Bisoprolol.
BambuterolBisoprolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Bisoprolol.
BenazeprilBenazepril may increase the hypotensive activities of Bisoprolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bisoprolol.
BenmoxinBenmoxin may increase the hypotensive activities of Bisoprolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Bisoprolol.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BepridilBisoprolol may increase the hypotensive activities of Bepridil.
BeractantBisoprolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Bisoprolol.
BethanecholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Bisoprolol.
BexaroteneThe serum concentration of Bisoprolol can be decreased when it is combined with Bexarotene.
BimatoprostBisoprolol may increase the hypotensive activities of Bimatoprost.
BoceprevirThe metabolism of Bisoprolol can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Bisoprolol can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bisoprolol can be decreased when it is combined with Bosentan.
BosentanBisoprolol may increase the hypotensive activities of Bosentan.
BretyliumBretylium may increase the bradycardic activities of Bisoprolol.
BretyliumBisoprolol may increase the hypotensive activities of Bretylium.
BrimonidineBisoprolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Bisoprolol.
BromfenacBromfenac may decrease the antihypertensive activities of Bisoprolol.
BromocriptineBisoprolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BumetanideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Bumetanide.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Bisoprolol.
BupranololBisoprolol may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Bisoprolol can be decreased when combined with Bupropion.
CabergolineBisoprolol may increase the vasoconstricting activities of Cabergoline.
CalfactantBisoprolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.
CandesartanBisoprolol may increase the hypotensive activities of Candesartan.
CandoxatrilBisoprolol may increase the hypotensive activities of Candoxatril.
CaptoprilBisoprolol may increase the hypotensive activities of Captopril.
CarbacholThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Carbachol.
CarbamazepineThe metabolism of Bisoprolol can be increased when combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Bisoprolol.
CarprofenCarprofen may decrease the antihypertensive activities of Bisoprolol.
CarteololCarteolol may increase the hypotensive activities of Bisoprolol.
CarvedilolBisoprolol may increase the hypotensive activities of Carvedilol.
CastanospermineCastanospermine may decrease the antihypertensive activities of Bisoprolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Bisoprolol.
CeliprololBisoprolol may increase the hypotensive activities of Celiprolol.
CeritinibBisoprolol may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Bisoprolol can be increased when it is combined with Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Bisoprolol.
ChlorothiazideBisoprolol may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Bisoprolol.
ChlorpropamideBisoprolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bisoprolol.
CholecalciferolThe metabolism of Bisoprolol can be decreased when combined with Cholecalciferol.
CilazaprilBisoprolol may increase the hypotensive activities of Cilazapril.
CimetidineThe metabolism of Bisoprolol can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Bisoprolol can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of Bisoprolol can be decreased when combined with Citalopram.
ClarithromycinThe metabolism of Bisoprolol can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Bisoprolol can be decreased when combined with Clemastine.
ClenbuterolBisoprolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.
ClobazamThe metabolism of Bisoprolol can be decreased when combined with Clobazam.
ClomipramineThe serum concentration of Bisoprolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Bisoprolol.
ClonixinClonixin may decrease the antihypertensive activities of Bisoprolol.
ClotrimazoleThe metabolism of Bisoprolol can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Bisoprolol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Bisoprolol can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Bisoprolol can be decreased when combined with Cocaine.
ConivaptanThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.
CoumaphosCoumaphos may increase the bradycardic activities of Bisoprolol.
CrizotinibThe metabolism of Bisoprolol can be decreased when combined with Crizotinib.
CrizotinibBisoprolol may increase the bradycardic activities of Crizotinib.
CryptenamineBisoprolol may increase the hypotensive activities of Cryptenamine.
CyclosporineThe metabolism of Bisoprolol can be decreased when combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Bisoprolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Bisoprolol.
DabrafenibThe serum concentration of Bisoprolol can be decreased when it is combined with Dabrafenib.
DapagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Bisoprolol can be increased when it is combined with Dapoxetine.
DarifenacinThe metabolism of Bisoprolol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Bisoprolol can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Bisoprolol can be increased when it is combined with Dasatinib.
DebrisoquinBisoprolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Bisoprolol.
DeferasiroxThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Bisoprolol can be decreased when combined with Delavirdine.
DemecariumDemecarium may increase the bradycardic activities of Bisoprolol.
DeserpidineBisoprolol may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Bisoprolol can be decreased when combined with Desipramine.
DeslanosideBisoprolol may increase the bradycardic activities of Deslanoside.
DexamethasoneThe serum concentration of Bisoprolol can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dexmedetomidine.
DiazoxideDiazoxide may increase the hypotensive activities of Bisoprolol.
DichlorvosDichlorvos may increase the bradycardic activities of Bisoprolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Bisoprolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Diclofenamide.
DiflunisalDiflunisal may decrease the antihypertensive activities of Bisoprolol.
DigitoxinBisoprolol may increase the bradycardic activities of Digitoxin.
DigoxinBisoprolol may increase the bradycardic activities of Digoxin.
DihydroergotamineBisoprolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineThe metabolism of Bisoprolol can be decreased when combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Bisoprolol.
DinutuximabThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dinutuximab.
DiphenhydramineThe metabolism of Bisoprolol can be decreased when combined with Diphenhydramine.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
DipivefrinBisoprolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Bisoprolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Bisoprolol.
DobutamineBisoprolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Bisoprolol.
DorzolamideBisoprolol may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Bisoprolol.
DoxycyclineThe metabolism of Bisoprolol can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Bisoprolol can be decreased when combined with Dronedarone.
DronedaroneBisoprolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Bisoprolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
DroxidopaBisoprolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineBisoprolol may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Bisoprolol can be decreased when combined with Duloxetine.
DyphyllineBisoprolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Bisoprolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Bisoprolol.
EfavirenzThe serum concentration of Bisoprolol can be decreased when it is combined with Efavirenz.
EfonidipineBisoprolol may increase the hypotensive activities of Efonidipine.
EliglustatThe metabolism of Bisoprolol can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Bisoprolol.
EnalaprilatBisoprolol may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Bisoprolol can be decreased when it is combined with Enzalutamide.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
EphedraBisoprolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Bisoprolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
EpinephrineBisoprolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Bisoprolol.
EplerenoneThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Eplerenone.
EpoprostenolBisoprolol may increase the hypotensive activities of Epoprostenol.
EprosartanBisoprolol may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateBisoprolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineBisoprolol may increase the vasoconstricting activities of Ergonovine.
ErgotamineBisoprolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
ErythromycinThe metabolism of Bisoprolol can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Bisoprolol can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Bisoprolol.
Etacrynic acidThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.
EtanerceptEtanercept may decrease the antihypertensive activities of Bisoprolol.
EtodolacEtodolac may decrease the antihypertensive activities of Bisoprolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Bisoprolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
EtoperidoneThe serum concentration of Bisoprolol can be increased when it is combined with Etoperidone.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Bisoprolol.
EtravirineThe serum concentration of Bisoprolol can be decreased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Bisoprolol.
exisulindexisulind may decrease the antihypertensive activities of Bisoprolol.
FelodipineBisoprolol may increase the hypotensive activities of Felodipine.
FenbufenFenbufen may decrease the antihypertensive activities of Bisoprolol.
FenfluramineThe serum concentration of Bisoprolol can be increased when it is combined with Fenfluramine.
FenoldopamBisoprolol may increase the hypotensive activities of Fenoldopam.
FenoprofenFenoprofen may decrease the antihypertensive activities of Bisoprolol.
FenoterolBisoprolol may decrease the bronchodilatory activities of Fenoterol.
FenthionFenthion may increase the bradycardic activities of Bisoprolol.
FingolimodBisoprolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Bisoprolol.
FluconazoleThe metabolism of Bisoprolol can be decreased when combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Bisoprolol.
FluoxetineThe serum concentration of Bisoprolol can be increased when it is combined with Fluoxetine.
FluphenazineFluphenazine may increase the hypotensive activities of Bisoprolol.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Bisoprolol.
FluvoxamineThe metabolism of Bisoprolol can be decreased when combined with Fluvoxamine.
FormoterolBisoprolol may decrease the bronchodilatory activities of Formoterol.
FosamprenavirThe metabolism of Bisoprolol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Bisoprolol can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Bisoprolol.
FosphenytoinThe metabolism of Bisoprolol can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Bisoprolol.
FurosemideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Furosemide.
Fusidic AcidThe serum concentration of Bisoprolol can be increased when it is combined with Fusidic Acid.
GalantamineGalantamine may increase the bradycardic activities of Bisoprolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Bisoprolol.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Bisoprolol.
GlibornurideBisoprolol may increase the hypoglycemic activities of Glibornuride.
GliclazideBisoprolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideBisoprolol may increase the hypoglycemic activities of Glimepiride.
GlipizideBisoprolol may increase the hypoglycemic activities of Glipizide.
GliquidoneBisoprolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideBisoprolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideBisoprolol may increase the hypoglycemic activities of Glyburide.
GTS-21The risk or severity of adverse effects can be increased when Bisoprolol is combined with GTS-21.
GuanabenzBisoprolol may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Bisoprolol.
GuanethidineBisoprolol may increase the hypotensive activities of Guanethidine.
GuanfacineBisoprolol may increase the hypotensive activities of Guanfacine.
HaloperidolThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.
HexamethoniumBisoprolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Bisoprolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Bisoprolol.
Huperzine AHuperzine A may increase the bradycardic activities of Bisoprolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Bisoprolol.
HydralazineBisoprolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideBisoprolol may increase the hypotensive activities of Hydrochlorothiazide.
HydroflumethiazideBisoprolol may increase the hypotensive activities of Hydroflumethiazide.
HydroxychloroquineThe metabolism of Bisoprolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Bisoprolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Bisoprolol.
IcatibantIcatibant may decrease the antihypertensive activities of Bisoprolol.
IdelalisibThe serum concentration of Bisoprolol can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Bisoprolol.
ImatinibThe metabolism of Bisoprolol can be decreased when combined with Imatinib.
ImipramineThe metabolism of Bisoprolol can be decreased when combined with Imipramine.
IndacaterolBisoprolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Bisoprolol can be increased when it is combined with Indalpine.
IndapamideBisoprolol may increase the hypotensive activities of Indapamide.
IndenololBisoprolol may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Bisoprolol can be decreased when combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Bisoprolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Bisoprolol.
IndoraminBisoprolol may increase the hypotensive activities of Indoramin.
Insulin PorkBisoprolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Bisoprolol.
IproniazidIproniazid may increase the hypotensive activities of Bisoprolol.
IrbesartanBisoprolol may increase the hypotensive activities of Irbesartan.
IsavuconazoniumThe metabolism of Bisoprolol can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bisoprolol.
IsoetarineBisoprolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Bisoprolol.
IsoniazidThe metabolism of Bisoprolol can be decreased when combined with Isoniazid.
IsoprenalineBisoprolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Mononitrate.
IsoxicamIsoxicam may decrease the antihypertensive activities of Bisoprolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Bisoprolol.
ItraconazoleThe metabolism of Bisoprolol can be decreased when combined with Itraconazole.
IvabradineBisoprolol may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Bisoprolol can be increased when it is combined with Ivacaftor.
KebuzoneKebuzone may decrease the antihypertensive activities of Bisoprolol.
KetoconazoleThe metabolism of Bisoprolol can be decreased when combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Bisoprolol.
KetorolacKetorolac may decrease the antihypertensive activities of Bisoprolol.
LabetalolLabetalol may increase the hypotensive activities of Bisoprolol.
LacidipineBisoprolol may increase the hypotensive activities of Lacidipine.
LacosamideBisoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideBisoprolol may increase the bradycardic activities of Lanreotide.
LatanoprostBisoprolol may increase the hypotensive activities of Latanoprost.
LeflunomideLeflunomide may decrease the antihypertensive activities of Bisoprolol.
LercanidipineLercanidipine may increase the hypotensive activities of Bisoprolol.
LevobunololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Levobunolol.
LevodopaBisoprolol may increase the orthostatic hypotensive activities of Levodopa.
LevomilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Levomilnacipran.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Bisoprolol.
LisinoprilBisoprolol may increase the hypotensive activities of Lisinopril.
LobelineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Lobeline.
LofexidineBisoprolol may increase the hypotensive activities of Lofexidine.
LopinavirThe metabolism of Bisoprolol can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Bisoprolol can be decreased when combined with Lorcaserin.
LornoxicamLornoxicam may decrease the antihypertensive activities of Bisoprolol.
LosartanBisoprolol may increase the hypotensive activities of Losartan.
LovastatinThe metabolism of Bisoprolol can be decreased when combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Bisoprolol.
Lu AA21004The serum concentration of Bisoprolol can be increased when it is combined with Lu AA21004.
LucinactantBisoprolol may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Bisoprolol can be increased when it is combined with Luliconazole.
LumefantrineThe metabolism of Bisoprolol can be decreased when combined with Lumefantrine.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Bisoprolol.
MacitentanBisoprolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Bisoprolol.
MalathionMalathion may increase the bradycardic activities of Bisoprolol.
ManidipineBisoprolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Mannitol.
MasoprocolMasoprocol may decrease the antihypertensive activities of Bisoprolol.
MebanazineMebanazine may increase the hypotensive activities of Bisoprolol.
MecamylamineBisoprolol may increase the hypotensive activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Bisoprolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Bisoprolol.
MefloquineMefloquine may increase the bradycardic activities of Bisoprolol.
MeloxicamMeloxicam may decrease the antihypertensive activities of Bisoprolol.
MemantineMemantine may increase the bradycardic activities of Bisoprolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Bisoprolol.
MesalazineMesalazine may decrease the antihypertensive activities of Bisoprolol.
MesoridazineMesoridazine may increase the hypotensive activities of Bisoprolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Bisoprolol.
MethacholineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methacholine.
MethadoneThe metabolism of Bisoprolol can be decreased when combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
MethazolamideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Bisoprolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Bisoprolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bisoprolol.
MethyldopaBisoprolol may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Bisoprolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bisoprolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bisoprolol.
MetipranololBisoprolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Bisoprolol.
MetoprololMetoprolol may increase the hypotensive activities of Bisoprolol.
MibefradilBisoprolol may increase the hypotensive activities of Mibefradil.
MidodrineBisoprolol may increase the bradycardic activities of Midodrine.
MifepristoneThe metabolism of Bisoprolol can be decreased when combined with Mifepristone.
MilnacipranThe serum concentration of Bisoprolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Bisoprolol.
MinoxidilMinoxidil may increase the hypotensive activities of Bisoprolol.
MirabegronThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Bisoprolol can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the hypotensive activities of Bisoprolol.
ModafinilThe serum concentration of Bisoprolol can be decreased when it is combined with Modafinil.
MoexiprilBisoprolol may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Bisoprolol.
MoricizineMoricizine may increase the hypotensive activities of Bisoprolol.
MoxonidineBisoprolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Bisoprolol.
NadololBisoprolol may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Bisoprolol can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the antihypertensive activities of Bisoprolol.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
NaproxenNaproxen may decrease the antihypertensive activities of Bisoprolol.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Bisoprolol.
NebivololBisoprolol may increase the hypotensive activities of Nebivolol.
NefazodoneThe metabolism of Bisoprolol can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Bisoprolol can be decreased when combined with Nelfinavir.
NeostigmineNeostigmine may increase the bradycardic activities of Bisoprolol.
NepafenacNepafenac may decrease the antihypertensive activities of Bisoprolol.
NesiritideThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nesiritide.
NetupitantThe serum concentration of Bisoprolol can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Bisoprolol can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Bisoprolol.
NicardipineBisoprolol may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Bisoprolol.
NicotineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Bisoprolol.
NifedipineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Bisoprolol.
NiguldipineBisoprolol may increase the hypotensive activities of Niguldipine.
NilotinibThe metabolism of Bisoprolol can be decreased when combined with Nilotinib.
NilvadipineBisoprolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Bisoprolol.
NimodipineNimodipine may increase the hypotensive activities of Bisoprolol.
NisoldipineNisoldipine may increase the hypotensive activities of Bisoprolol.
NitrendipineBisoprolol may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Bisoprolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
NorepinephrineBisoprolol may decrease the bronchodilatory activities of Norepinephrine.
ObinutuzumabBisoprolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Bisoprolol.
OctreotideOctreotide may increase the bradycardic activities of Bisoprolol.
OlanzapineThe serum concentration of Bisoprolol can be increased when it is combined with Olanzapine.
OlaparibThe metabolism of Bisoprolol can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Bisoprolol.
OlodaterolBisoprolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Bisoprolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Bisoprolol.
OmapatrilatBisoprolol may increase the hypotensive activities of Omapatrilat.
OrciprenalineBisoprolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Bisoprolol.
OsimertinibThe serum concentration of Bisoprolol can be increased when it is combined with Osimertinib.
OuabainBisoprolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Bisoprolol.
OxprenololBisoprolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Bisoprolol.
PalbociclibThe serum concentration of Bisoprolol can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
PanobinostatThe metabolism of Bisoprolol can be decreased when combined with Panobinostat.
PapaverineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.
ParecoxibParecoxib may decrease the antihypertensive activities of Bisoprolol.
PargylineBisoprolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Bisoprolol can be increased when it is combined with Paroxetine.
PasireotideBisoprolol may increase the bradycardic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Bisoprolol can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololBisoprolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Bisoprolol.
PentoliniumBisoprolol may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Bisoprolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
PerindoprilBisoprolol may increase the hypotensive activities of Perindopril.
PerphenazinePerphenazine may increase the hypotensive activities of Bisoprolol.
PhenelzinePhenelzine may increase the hypotensive activities of Bisoprolol.
PheniprazinePheniprazine may increase the hypotensive activities of Bisoprolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bisoprolol.
PhenoxybenzamineBisoprolol may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bisoprolol.
PhentolamineBisoprolol may increase the hypotensive activities of Phentolamine.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Bisoprolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
PhenylpropanolamineBisoprolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhenytoinThe metabolism of Bisoprolol can be increased when combined with Phenytoin.
PhysostigminePhysostigmine may increase the bradycardic activities of Bisoprolol.
PilocarpineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Bisoprolol.
PinacidilBisoprolol may increase the hypotensive activities of Pinacidil.
PindololBisoprolol may increase the hypotensive activities of Pindolol.
PirbuterolBisoprolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Bisoprolol.
PirlindolePirlindole may increase the hypotensive activities of Bisoprolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Bisoprolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Bisoprolol.
PolythiazideBisoprolol may increase the hypotensive activities of Polythiazide.
Poractant alfaBisoprolol may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe metabolism of Bisoprolol can be decreased when combined with Posaconazole.
PrazosinPrazosin may increase the hypotensive activities of Bisoprolol.
PrimaquineThe metabolism of Bisoprolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Bisoprolol.
ProcaterolBisoprolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Bisoprolol.
PromazinePromazine may increase the hypotensive activities of Bisoprolol.
PromethazinePromethazine may increase the hypotensive activities of Bisoprolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Bisoprolol.
PropafenoneThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.
PropafenoneBisoprolol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Bisoprolol.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
PTC299PTC299 may decrease the antihypertensive activities of Bisoprolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Bisoprolol.
QuetiapineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Quetiapine.
QuinaprilBisoprolol may increase the hypotensive activities of Quinapril.
QuinidineThe metabolism of Bisoprolol can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Bisoprolol.
RamiprilRamipril may increase the hypotensive activities of Bisoprolol.
RanolazineThe metabolism of Bisoprolol can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Bisoprolol.
RegorafenibRegorafenib may increase the bradycardic activities of Bisoprolol.
RemikirenRemikiren may increase the hypotensive activities of Bisoprolol.
RescinnamineBisoprolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Bisoprolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Bisoprolol.
RifabutinThe metabolism of Bisoprolol can be increased when combined with Rifabutin.
RifampicinThe metabolism of Bisoprolol can be increased when combined with Rifampicin.
RifapentineThe metabolism of Bisoprolol can be increased when combined with Rifapentine.
RiociguatBisoprolol may increase the hypotensive activities of Riociguat.
RisperidoneBisoprolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
RitodrineBisoprolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe metabolism of Bisoprolol can be decreased when combined with Ritonavir.
RituximabBisoprolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Bisoprolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Bisoprolol.
RolapitantThe metabolism of Bisoprolol can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of Bisoprolol can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Bisoprolol.
SafrazineSafrazine may increase the hypotensive activities of Bisoprolol.
SalbutamolBisoprolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Bisoprolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Bisoprolol.
SalmeterolBisoprolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Bisoprolol.
SaprisartanBisoprolol may increase the hypotensive activities of Saprisartan.
SaquinavirThe metabolism of Bisoprolol can be decreased when combined with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Bisoprolol.
SelegilineSelegiline may increase the hypotensive activities of Bisoprolol.
SelexipagBisoprolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Bisoprolol.
SertralineThe serum concentration of Bisoprolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Bisoprolol.
SilodosinBisoprolol may increase the orthostatic hypotensive activities of Silodosin.
SiltuximabThe serum concentration of Bisoprolol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Bisoprolol can be increased when it is combined with Simeprevir.
SitaxentanBisoprolol may increase the hypotensive activities of Sitaxentan.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Bisoprolol.
SpiraprilBisoprolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoprolol.
SRT501SRT501 may decrease the antihypertensive activities of Bisoprolol.
St. John's WortThe serum concentration of Bisoprolol can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Bisoprolol can be increased when it is combined with Stiripentol.
SufentanilBisoprolol may increase the bradycardic activities of Sufentanil.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Bisoprolol.
SulfisoxazoleThe metabolism of Bisoprolol can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the antihypertensive activities of Bisoprolol.
SuprofenSuprofen may decrease the antihypertensive activities of Bisoprolol.
TacrineTacrine may increase the bradycardic activities of Bisoprolol.
TadalafilTadalafil may increase the antihypertensive activities of Bisoprolol.
TamsulosinBisoprolol may increase the orthostatic hypotensive activities of Tamsulosin.
TelaprevirThe metabolism of Bisoprolol can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Bisoprolol can be decreased when combined with Telithromycin.
TelmisartanBisoprolol may increase the hypotensive activities of Telmisartan.
TemocaprilBisoprolol may increase the hypotensive activities of Temocapril.
TenoxicamTenoxicam may decrease the antihypertensive activities of Bisoprolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Bisoprolol.
TerazosinThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Terazosin.
TerbinafineThe metabolism of Bisoprolol can be decreased when combined with Terbinafine.
TerbutalineBisoprolol may decrease the bronchodilatory activities of Terbutaline.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Bisoprolol.
TerlipressinBisoprolol may increase the hypotensive activities of Terlipressin.
TheophyllineBisoprolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Bisoprolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Bisoprolol.
ThiopentalThiopental may increase the hypotensive activities of Bisoprolol.
ThioridazineThioridazine may increase the hypotensive activities of Bisoprolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Bisoprolol.
TiboloneBisoprolol may increase the hypotensive activities of Tibolone.
TiclopidineThe metabolism of Bisoprolol can be decreased when combined with Ticlopidine.
TicrynafenBisoprolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Bisoprolol.
TipranavirThe metabolism of Bisoprolol can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Tizanidine.
TocilizumabThe serum concentration of Bisoprolol can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Bisoprolol.
TolazamideBisoprolol may increase the hypoglycemic activities of Tolazamide.
TolazolineBisoprolol may increase the hypotensive activities of Tolazoline.
TolbutamideBisoprolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Bisoprolol.
TolmetinTolmetin may decrease the antihypertensive activities of Bisoprolol.
ToloxatoneToloxatone may increase the hypotensive activities of Bisoprolol.
TorasemideTorasemide may increase the hypotensive activities of Bisoprolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Bisoprolol.
TranilastTranilast may decrease the antihypertensive activities of Bisoprolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Bisoprolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Bisoprolol.
TravoprostTravoprost may increase the hypotensive activities of Bisoprolol.
TrazodoneThe serum concentration of Bisoprolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Bisoprolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Bisoprolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Bisoprolol.
TrichlormethiazideBisoprolol may increase the hypotensive activities of Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Bisoprolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Bisoprolol.
TrimazosinBisoprolol may increase the hypotensive activities of Trimazosin.
TrimethaphanBisoprolol may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Bisoprolol.
TubocurarineTubocurarine may increase the bradycardic activities of Bisoprolol.
UdenafilUdenafil may increase the antihypertensive activities of Bisoprolol.
UnoprostoneBisoprolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Bisoprolol.
ValsartanValsartan may increase the hypotensive activities of Bisoprolol.
VardenafilVardenafil may increase the antihypertensive activities of Bisoprolol.
VareniclineThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Varenicline.
VenlafaxineThe metabolism of Bisoprolol can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Verapamil.
VilanterolBisoprolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Bisoprolol can be increased when it is combined with Vilazodone.
VoriconazoleThe metabolism of Bisoprolol can be decreased when combined with Voriconazole.
VortioxetineThe serum concentration of Bisoprolol can be increased when it is combined with Vortioxetine.
XylometazolineBisoprolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Bisoprolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Bisoprolol.
ZileutonZileuton may decrease the antihypertensive activities of Bisoprolol.
ZimelidineThe serum concentration of Bisoprolol can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Bisoprolol can be decreased when combined with Ziprasidone.
ZomepiracZomepirac may decrease the antihypertensive activities of Bisoprolol.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Breed JG, Ciampricotti R, Tromp GP, Valster FA, Lageweg E, Van Bortel LM: Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol. 1992;20(5):750-5. [PubMed:1280737 ]
  2. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050 ]
  4. Lipworth BJ, Irvine NA, McDevitt DG: A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol. 1991;40(2):135-9. [PubMed:1676675 ]
  5. Mauz AB, Pelzer H: Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. J Cardiovasc Pharmacol. 1990 Mar;15(3):421-7. [PubMed:1691366 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Brouri F, Hanoun N, Mediani O, Saurini F, Hamon M, Vanhoutte PM, Lechat P: Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis. Eur J Pharmacol. 2004 Feb 6;485(1-3):227-34. [PubMed:14757145 ]
  2. Bruck H, Poller U, Lussenhop H, Ponicke K, Temme T, Heusch G, Philipp T, Brodde OE: Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):361-8. Epub 2004 Oct 23. [PubMed:15526107 ]
  3. Motomura S, Reinhard-Zerkowski H, Daul A, Brodde OE: On the physiologic role of beta-2 adrenoceptors in the human heart: in vitro and in vivo studies. Am Heart J. 1990 Mar;119(3 Pt 1):608-19. [PubMed:1968697 ]
  4. Brodde OE: Bisoprolol (EMD 33512), a highly selective beta 1-adrenoceptor antagonist: in vitro and in vivo studies. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S29-35. [PubMed:2439795 ]
  5. Daul A, Johnston T, Reher M, Kruger M, Brodde OE: Differential haemodynamic effects induced by beta 1-(bisoprolol) or beta 2-(ICI 118,551) adrenoceptor blockade in man. J Hypertens Suppl. 1986 Dec;4(6):S99-102. [PubMed:2886573 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. J Pharm Sci. 1998 Mar;87(3):289-94. [PubMed:9523980 ]
  2. Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans. Life Sci. 1998;63(13):1097-108. [PubMed:9763205 ]
  3. Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H: Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol. 2005 Nov;46(5):713-20. [PubMed:16220080 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23